Restoring SIRT7 to protect aging blood stem cells
Targeting SIRT7 Regulation of Mitochondrial Quality Control to Short Circuit Age-Related Diseases of the Hematopoietic System
['FUNDING_OTHER'] · UNIVERSITY OF KENTUCKY · NIH-11251305
This project aims to restore SIRT7 and improve mitochondrial cleanup in older blood stem cells to help prevent age-related blood problems, leukemia, and heart disease.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF KENTUCKY (nih funded) |
| Locations | 1 site (LEXINGTON, UNITED STATES) |
| Trial ID | NIH-11251305 on ClinicalTrials.gov |
What this research studies
If I'm worried about getting blood cancers or heart disease as I age, this research focuses on a protein called SIRT7 that helps cells handle stress and keep mitochondria healthy. The team uses lab experiments and animal models to see how loss of SIRT7 disrupts mitochondrial quality control in blood stem cells and drives clonal expansions linked to leukemia and cardiovascular risk. By targeting the SIRT7–mitoQC pathway they hope to reverse or prevent those age-related changes in the hematopoietic system. Findings could point toward new ways to keep immune and blood-forming cells healthier with age.
Who could benefit from this research
Good fit: Ideal candidates would be older adults with evidence of clonal hematopoiesis or people at higher risk for age-related blood disorders or cardiovascular disease.
Not a fit: Younger individuals without age-related blood stem cell changes or people with advanced, treatment-resistant leukemia are unlikely to benefit directly from this basic research.
Why it matters
Potential benefit: Could lead to treatments that keep blood stem cells healthier with age, reducing the chance of clonal hematopoiesis, leukemia, and related cardiovascular problems.
How similar studies have performed: Previous laboratory and animal studies have linked SIRT7 to aging and stem cell function, but targeting the SIRT7–mitochondrial quality control pathway as a therapy in humans is largely untested.
Where this research is happening
LEXINGTON, UNITED STATES
- UNIVERSITY OF KENTUCKY — LEXINGTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MOHRIN, MARY — UNIVERSITY OF KENTUCKY
- Study coordinator: MOHRIN, MARY
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Center, Cardiovascular Diseases